Achilles Therapeutics plc (NASDAQ:ACHL) Sees Large Decline in Short Interest

Achilles Therapeutics plc (NASDAQ:ACHL) saw a large drop in short interest in April. As of April 15th, there was short interest totalling 37,800 shares, a drop of 49.5% from the March 31st total of 74,800 shares. Currently, 0.1% of the company’s stock are short sold. Based on an average trading volume of 770,200 shares, the days-to-cover ratio is presently 0.0 days.

Achilles Therapeutics Stock Performance

Shares of ACHL stock opened at $0.76 on Friday. Achilles Therapeutics has a one year low of $0.74 and a one year high of $1.76. The company’s 50-day moving average is $1.11 and its 200 day moving average is $0.96. The company has a market capitalization of $30.31 million, a price-to-earnings ratio of -0.44 and a beta of 1.09.

Achilles Therapeutics (NASDAQ:ACHL) last announced its quarterly earnings results on Thursday, April 4th. The company reported ($0.46) earnings per share (EPS) for the quarter. As a group, research analysts predict that Achilles Therapeutics will post -1.34 earnings per share for the current fiscal year.

Institutional Trading of Achilles Therapeutics

A hedge fund recently bought a new stake in Achilles Therapeutics stock. Vestal Point Capital LP purchased a new stake in shares of Achilles Therapeutics plc (NASDAQ:ACHL) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 108,083 shares of the company’s stock, valued at approximately $96,000. Vestal Point Capital LP owned about 0.27% of Achilles Therapeutics as of its most recent SEC filing. 56.38% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages recently commented on ACHL. Piper Sandler reissued a “neutral” rating and set a $2.00 price objective (down from $8.00) on shares of Achilles Therapeutics in a research report on Friday, April 5th. Chardan Capital cut their price objective on shares of Achilles Therapeutics from $11.00 to $6.00 and set a “buy” rating on the stock in a research report on Friday, April 5th.

About Achilles Therapeutics

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma.